Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (Cardiovascular Drugs and Therapy, (2020), 34, 3, (357-370), 10.1007/s10557-019-06919-4)

The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ‘intraventricular septum wall thickness’ should have been given as ‘interventricular septum wall thickness’. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend ‘Low risk – Neither above at baseline’ should read ‘Low risk – Neither above threshold at baseline’; in Table 4, the rows ‘Mild: eGFR > 60 to < 90 ml/min/1.73 m²’ and ‘Moderate: eGFR > 30 to < 60 ml/min/1.73 m²’ should read ‘Mild: eGFR ≥ 60 to < 90 ml/min/1.73 m²’ and ‘Moderate: eGFR ≥ 30 to < 60 ml/min/1.73 m²’, respectively. The original article also contained a mistake in the text of the Pharmacokinetics sub-section of Results; ‘There were no apparent differences in revusiran C_maxbetween patients with mild (eGFR: 30 and < 60 ml/min/1.73 m²) or moderate (eGFR: 60 to < 90 ml/min/1.73 m²) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m²) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)’ should read ‘There were no apparent differences in revusiran C_maxbetween patients with mild (eGFR: ≥ 60 to < 90 ml/min/1.73 m²) or moderate (eGFR: ≥ 30 and < 60 ml/min/1.73 m²) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m²) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)’.